In an interview conducted by EMJ, a leading expert from the field of cardiology and cardiovascular disease provided their perspectives on Phase II data and the design of the Phase II trial for aficamten. A cardiac myosin inhibitor, aficamten targets the underlying pathophysiology of hypertrophic cardiomyopathy.
EMJ Cardiology 10 [Supplement 1] . 2022
Latest articlesAll articles
Heated Tobacco Products and Chronic Obstructive Pulmonary Disease: A Narrative Review of Peer-Reviewed Publications
An estimated 65 million people worldwide have moderate or severe chronic obstructive pulmonary disease (COPD), an umbrella term used to describe a group of progressive lung diseases that obstruct airflow such as emphysema and chronic bronchitis. Smoking contributes to an estimated 90% of COPD cases, as the harmful chemicals produced during tobacco combustion damage the lungs and airways. Although smoking cessation is the only intervention shown to improve COPD prognosis in smokers, many patients who try to quit continue to smoke.
Caseous Mitral Annular Calcification Presenting as Retinal Artery Occlusion
Caseous mitral annular calcification (CMAC), sometimes called liquefaction necrosis of mitral annular calcification (MAC), is a rare variant of MAC, a chronic degenerative process that progresses with age.
Current Evidence on Tobacco Harm Reduction in Pneumology: Interviews with Two Key Opinion Leaders
The harmful effects of cigarette smoke on human health are well documented and supported by evidence from preclinical, clinical, and epidemiological studies. Cigarette smoking damages multiple organs and leads to 8 million global deaths per year from direct use and passive exposure of cigarette smoke to non-smokers.